Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07063212 · ClinicalTrials.gov registry record · Phase 2
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
A Phase 2 study of Squamous Cell Carcinoma of Head and Neck and Oropharynx Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 7
- Study locations
NCT07063212: Recruiting Phase 2 study of Squamous Cell Carcinoma of Head and Neck and Oropharynx Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT07063212 is a Phase 2 study of Squamous Cell Carcinoma of Head and Neck and Oropharynx Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 40 participants, below the 169-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (76% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07063212, a Phase 2 study of Squamous Cell Carcinoma of Head and Neck and Oropharynx Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).
Primary Outcome
To evaluated objective response rate (ORR; complete response \[CR\] + partial response \[PR\]), by RECIST v1.1, in the study cohort.
Conditions Studied
Interventions
- DRUG Cetuximab
- DRUG Sacituzumab Govitecan
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activites) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-07-02 |
| Est. Completion | 2028-01-02 |
| Phase | Phase 2 |
What NCT07063212 shows while recruiting
NCT07063212 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 169-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (76% lower).
The record links to 10 conditions, with Squamous Cell Carcinoma of Head and Neck appearing as the primary indexed condition, and to 2 interventions - of which Cetuximab is the first listed.
NCT07063212 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT07063212 about?
NCT07063212 is a clinical study titled "A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)". The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).
What is the current status of trial NCT07063212?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-07-02. Estimated completion is 2028-01-02.
What conditions does trial NCT07063212 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma of Head and Neck, Oropharynx Cancer, Oral Cavity Cancer, Larynx Cancer, Oropharynx Squamous Cell Carcinoma.
What interventions are being tested in trial NCT07063212?
The interventions under investigation include: Cetuximab (DRUG), Sacituzumab Govitecan (DRUG).
Who is sponsoring clinical trial NCT07063212?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07063212 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma of Head and Neck
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07063212's enrollment target sits among peer trials
40 27th of 37 higher than 11 of 37 other Squamous Cell Carcinoma of Head and Neck trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Squamous Cell Carcinoma of Head and Neck trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
RECRUITING · Phase 2
-
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
RECRUITING · Phase 2
-
5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
RECRUITING · Phase 2
-
Pembrolizumab Plus Olaparib in LA-HNSCC
ACTIVE NOT RECRUITING · Phase 2
-
ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI